TGTX TG THERAPEUTICS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Fully integrated biotech focused on novel treatments for B-cell diseases, principally commercializing BRIUMVI for relapsing multiple sclerosis (RMS)
• • New initiatives: Launched Next In MS™ awareness platform with Christina Applegate; initiated Phase 3 enrollment for subcutaneous ublituximab; dosed first patient with azer-cel CAR T therapy in Phase 1 for progressive MS

Risk Factors

• • Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors
• • Management oversight of cybersecurity risks with Board receiving regular reports on material threats and IT security effectiveness

Management Discussion & Analysis

• • No revenue or profitability data provided in the excerpt
• • No segment performance or cash flow information disclosed

Risk Factors

• • New risk: post-marketing requirements for BRIUMVI including long-term safety studies and pediatric/pregnancy evaluation triggered by FDA approval conditions
• • Most updated risk: commercialization challenges due to expanding global operations; BRIUMVI launched in Europe Feb 2024 with risks in third-party partnerships impacting sales control

What are the latest TGTX SEC filings in 2026?

TG THERAPEUTICS, INC. (TGTX) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 20, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TGTX file its most recent 10-K annual report?

TG THERAPEUTICS, INC. (TGTX) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TGTX 10-Q quarterly reports?

TG THERAPEUTICS, INC. (TGTX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every TGTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TGTX filed recently?

TG THERAPEUTICS, INC. (TGTX)'s most recent 8-K was filed on March 20, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TGTX insider trading activity (Form 4)?

SignalX aggregates every TGTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TGTX file with the SEC?

TG THERAPEUTICS, INC. (TGTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TGTX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for TG THERAPEUTICS, INC. (TGTX).

What is TGTX's SEC CIK number?

TG THERAPEUTICS, INC. (TGTX)'s SEC CIK (Central Index Key) number is 1001316. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1001316 to look up all TGTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TGTX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from TG THERAPEUTICS, INC. (TGTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.